EcoDrugPlus

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSLBEG00000010077
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSLBEG00000025948
Gene Symbol: CHRM2A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSLBEG00000016241
Gene Symbol: CHRNA4B
1 Cross references
193 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSLBEG00000021961
Gene Symbol: F2R
1 Cross references
216 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSLBEG00000027117
Gene Symbol: F2R
2 Cross references
262 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSLBEG00000027145
Gene Symbol: F2R
2 Cross references
262 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSLBEG00000028380
Gene Symbol: LOC110002085
3 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSLBEG00000028370
Gene Symbol: F10
1 Cross references
240 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSLBEG00000022917
Gene Symbol: LOC109990904
2 Cross references
205 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSLBEG00000021341
Gene Symbol: CCDC6
3 Cross references
207 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSLBEG00000012136
Gene Symbol: LOC109976780
3 Cross references
278 Possible Orthologues:

Complement C5

Ensembl ID : ENSLBEG00000007642
Gene Symbol: C5
2 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).